var data={"title":"Radium-223: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Radium-223: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/576710?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=radium-223-patient-drug-information\" class=\"drug drug_patient\">see &quot;Radium-223: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421922\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Xofigo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20396983\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Radiopharmaceutical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421954\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Calculate administration volume using patient weight, radioactivity content (at the reference date), and decay correction factor; determine net patient dose immediately before and after administration with an appropriate radioisotope dose calibrator; refer to product labeling for further details. Prior to initial dose, ANC should be &ge;1,500/mm<sup>3</sup>, platelets &ge;100,000/mm<sup>3</sup>, and hemoglobin &ge;10 g/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer, castration-resistant with symptomatic bone metastases:</b> Males: IV: 55 kBq/kg (1.49 microcurie/kg) every 4 weeks for 6 doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421955\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421956\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 30 to 89 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling, (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421957\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); however, dosage adjustment is not likely needed because not metabolized hepatically or eliminated in bile.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421958\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">ANC &lt;1,000/mm<sup>3</sup> or platelets &lt;50,000/mm<sup>3</sup> (prior to subsequent doses): Withhold treatment until hematologic recovery; if recovery does not occur within 6 to 8 weeks from the last dose (despite supportive care), discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Compromised bone marrow reserve: Closely monitor; discontinue if life-threatening complications occur despite supportive care</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20482819\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xofigo: 1100 kBq/mL (30 microcurie/mL) (6 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421923\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421962\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer as a slow IV injection over 1 minute. Flush IV line or cannula before and after administration with saline. Radiopharmaceutical; use appropriate precautions for handling and disposal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20396906\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Prostate cancer:</b> Treatment of castration-resistant prostate cancer in patients with symptomatic bone metastases and no known visceral metastatic disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20397124\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Xofigo may be confused with Jevtana, Xgeva, Xtandi, Zometa, Zytiga</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20429125\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (36%), diarrhea (25%), vomiting (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (93%; grades 3/4: 6%), lymphocytopenia (72%; grades 3/4: 20%), leukopenia (35%; grades 3/4: 3%), thrombocytopenia (31%; grades 3/4: 1% to 6%), neutropenia (18%; grades 3/4: 1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Pancytopenia (2%; grades 3/4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reactions (erythema, pain, swelling: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure/insufficiency (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%: Aplastic anemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20396985\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Use in women who are or may become pregnant</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421928\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Hematologic toxicity, including anemia, lymphocytopenia, thrombocytopenia, leukopenia, and neutropenia commonly occur; monitor blood counts at baseline and prior to each dose. Bone marrow failure occurred in 2% of patients receiving radium Ra 223 dichloride in clinical studies (did not occur in patients who received placebo). Bone marrow failure may be prolonged and fatal (rare); may require blood transfusion support. Vascular hemorrhage due to thrombocytopenia has been reported. Infection may occur due to neutropenia. Prior to initial dose, ANC should be &ge;1,500/mm<sup>3</sup>, platelets &ge;100,000/mm<sup>3</sup>, and hemoglobin &ge;10 g/dL; prior to subsequent doses, ANC should be &ge;1,000/mm<sup>3</sup> and platelets &ge;50,000/mm<sup>3</sup>. Neutrophils and platelet nadirs typically occurred 2 to 3 weeks after administration; recovery generally occurred ~6 to 8 weeks after administration. If recovery does not occur within 6 to 8 weeks from the last dose (despite supportive care), treatment should be discontinued. Closely monitor patients with compromised bone marrow reserve; discontinue if life-threatening complications occur despite supportive care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dehydration: Dehydration may occur due to gastrointestinal adverse events (diarrhea, nausea, vomiting); monitor oral intake, hydration status, and urine output.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancies: Although fewer malignancies were reported for radium Ra 223 dichloride than for placebo (from clinical studies), long-term cumulative radiation exposure may increase the risk for malignancies (onset may be delayed). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chemotherapy: The safety and efficacy of concurrent chemotherapy have not been established. Due to the potential for additive bone marrow toxicity, concurrent use with chemotherapy is not recommended outside of a clinical trial. If chemotherapy, other systemic radioisotopes, or external radiotherapy are required, radium Ra 223 dichloride should be discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. Patients and caregivers should use the following precautions to minimize exposure:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- When handling bodily fluids, wear gloves and wash hands after handling.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">-\tWash any clothing soiled with radium Ra 223 dichloride promptly and separately from other clothing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">-\tWhere a normal toilet is available, use in preference to a urinal.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">-\tFlush toilet several times after use.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">-\tWash hands thoroughly after urination.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46440238\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46440235\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=89425&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421924\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421925\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Contraindicated in pregnancy; use is contraindicated in women who are or may become pregnant.  </p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Based on the mechanism of action, radium Ra 223 dichloride has the potential to cause fetal harm if administered during pregnancy. Not indicated for use in women. Men who are sexually active should use condoms during and for 6 months after completing treatment; their female partners of reproductive potential should use a highly effective contraceptive method during and for 6 months after treatment is completed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421927\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if radium Ra 223 dichloride is excreted in breast milk. Not indicated for use in women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421969\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential at baseline and prior to each dose. Monitor fluid intake, hydration status, and urine output. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421941\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Alpha particle-emitting isotope; emits high energy, short-range alpha particles which target bone metastases; mimics calcium to form complexes with bone mineral in areas with increased bone turnover. Alpha emission induces double strand DNA breaks in adjacent cells, which results in an antitumor effect on the bone metastases.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421943\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: A significant response in pain index was seen at week 2 (Nilsson 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Mean duration of pain relief: 44 days (Nilsson 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Primarily to the bone or excreted in to intestine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Decays (is not metabolized)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 11.4 days (Nilsson 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (13%); urine (2%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20616248\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Xofigo Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mcci/ml (1): $27,530.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23777455\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Xofigo (AT, AU, BM, CY, CZ, DE, DK, EE, ES, FR, HK, HR, HU, IS, JP, KR, LT, LU, LV, MT, MY, NL, NO, PL, PT, SE, SG, SI, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(30):3436-3448.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/radium-223-drug-information/abstract-text/25199761/pubmed\" target=\"_blank\" id=\"25199761\">25199761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoskin P, Sartor O, O'Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. <i>Lancet Oncol</i>. 2014;15(12):1397-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/radium-223-drug-information/abstract-text/25439694/pubmed\" target=\"_blank\" id=\"25439694\">25439694</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nilsson S, Franz&eacute;n L, Parker C, et al, &ldquo;Bone-Targeted Radium-223 in Symptomatic, Hormone-Refractory Prostate Cancer: A Randomised, Multicentre, Placebo-Controlled Phase II Study,&rdquo; <i>Lancet Oncol</i>, 2007, 8(7):587-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/radium-223-drug-information/abstract-text/17544845/pubmed\" target=\"_blank\" id=\"17544845\">17544845</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nilsson S, Strang P, Aksnes AK, et al, &ldquo;A Randomized, Dose-Response, Multicenter Phase II Study of Radium-223 Chloride for the Palliation of Painful Bone Metastases in Patients With Castration-Resistant Prostate Cancer,&rdquo; <i>Eur J Cancer</i>, 2012, 48(5):678-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/radium-223-drug-information/abstract-text/22341993/pubmed\" target=\"_blank\" id=\"22341993\">22341993</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker CC, Pascoe S, Chodacki A, et al, &ldquo;A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients With Bone Metastases and Castration-Resistant Prostate Cancer,&rdquo; <i>Eur Urol</i>, 2013, 63(2):189-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/radium-223-drug-information/abstract-text/23000088/pubmed\" target=\"_blank\" id=\"23000088\">23000088</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. <i>Lancet Oncol</i>. 2014;15(7):738-746.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/radium-223-drug-information/abstract-text/24836273/pubmed\" target=\"_blank\" id=\"24836273\">24836273</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xofigo (radium Ra 223 dichloride) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; February 2018.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 89425 Version 86.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20421922\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F20396983\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F20421954\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F20421955\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20421956\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20421957\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F20421958\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F20482819\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F20421923\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F20421962\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F20396906\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F20397124\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F20429125\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F20396985\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F20421928\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46440238\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46440235\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F20421924\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F20421925\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20421927\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F20421969\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F20421941\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F20421943\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F20616248\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23777455\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/89425|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=radium-223-patient-drug-information\" class=\"drug drug_patient\">Radium-223: Patient drug information</a></li></ul></div></div>","javascript":null}